B. Lyons

Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.

D. Alberts, C. Moinpour, G. Weiss, 2004, Gynecologic oncology.

Quality of life in advanced non-small-cell lung cancer: Results of a Southwest Oncology Group randomized trial

J. Crowley, K. Kelly, P. Grevstad, 2002, Quality of Life Research.

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

J. Wolchok, T. Powles, F. Hodi, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-187 Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in Non-Small Cell Lung Cancer (NSCLC) patients after prior chemotherapy

T. Dang, R. Herbst, V. Miller, 2005 .

A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.

J. Hou, K. Gross, L. Goldberg, 2015, Journal of the American Academy of Dermatology.

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Molly Brewer, Beth Y Karlan, Daniela Matei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Substituting proxy ratings for patient ratings in cancer clinical trials: An analysis based on a Southwest Oncology Group trial in patients with brain metastases

C. Moinpour, K. Chansky, C. M. Moinpour, 2000, Quality of Life Research.

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

A. D. Van den Abbeele, T. Dang, R. Herbst, 2007, Clinical Cancer Research.

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

David S Mendelson, M. Morris, H. Scher, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune-Modi fi ed Response Evaluation Criteria In Solid Tumors ( imRECIST ) : Re fi ning Guidelines to Assess the Clinical Bene fi t of Cancer Immunotherapy

J. Wolchok, T. Powles, F. Hodi, 2018 .